Arch Biopartners Inc. (ACHFF)
USD 1.1
(-7.56%)
USD 1.1
(-7.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.22 Million CAD | 385.54% |
| 2022 | 1.08 Million CAD | 21.14% |
| 2021 | 891.53 Thousand CAD | -80.3% |
| 2020 | 4.52 Million CAD | 92.96% |
| 2019 | 2.34 Million CAD | -25.96% |
| 2018 | 3.16 Million CAD | 68.45% |
| 2017 | 1.88 Million CAD | 91.8% |
| 2016 | 980.57 Thousand CAD | 5.84% |
| 2015 | 926.46 Thousand CAD | 148.97% |
| 2014 | 372.11 Thousand CAD | 113.4% |
| 2013 | 174.37 Thousand CAD | -44.56% |
| 2012 | 314.51 Thousand CAD | -26.57% |
| 2011 | 428.32 Thousand CAD | 215.09% |
| 2010 | 135.93 Thousand CAD | -25.22% |
| 2009 | 181.79 Thousand CAD | -83.1% |
| 2008 | 1.07 Million CAD | 34.91% |
| 2007 | 797.18 Thousand CAD | 38.75% |
| 2006 | 574.53 Thousand CAD | -32.49% |
| 2005 | 850.97 Thousand CAD | -61.19% |
| 2004 | 2.19 Million CAD | 58.91% |
| 2003 | 1.37 Million CAD | 516.35% |
| 2002 | 223.89 Thousand CAD | 13.53% |
| 2001 | 197.2 Thousand CAD | -86.62% |
| 2000 | 1.47 Million CAD | 79.84% |
| 1999 | 819.61 Thousand CAD | 24.09% |
| 1998 | 660.51 Thousand CAD | -46.45% |
| 1997 | 1.23 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1 Million CAD | 293.73% |
| 2024 Q2 | 1.05 Million CAD | 5.39% |
| 2024 Q3 | 389.82 Thousand CAD | -63.06% |
| 2023 Q2 | 896.03 Thousand CAD | -58.18% |
| 2023 Q3 | 474.3 Thousand CAD | -47.07% |
| 2023 Q4 | -516.88 Thousand CAD | -208.98% |
| 2023 FY | 5.24 Million CAD | 385.54% |
| 2023 Q1 | 2.14 Million CAD | 509.19% |
| 2022 Q4 | 351.74 Thousand CAD | 78.6% |
| 2022 Q3 | 196.94 Thousand CAD | -53.38% |
| 2022 Q2 | 422.43 Thousand CAD | 287.86% |
| 2022 Q1 | 108.91 Thousand CAD | 114.36% |
| 2022 FY | 1.08 Million CAD | 21.14% |
| 2021 Q1 | 1.6 Million CAD | 3.97% |
| 2021 Q4 | -758.29 Thousand CAD | 22.03% |
| 2021 FY | 891.53 Thousand CAD | -80.3% |
| 2021 Q3 | -972.51 Thousand CAD | -194.02% |
| 2021 Q2 | 1.03 Million CAD | -35.72% |
| 2020 Q1 | 723.1 Thousand CAD | -27.68% |
| 2020 Q2 | 79.32 Thousand CAD | -89.03% |
| 2020 Q3 | 2.17 Million CAD | 2642.96% |
| 2020 Q4 | 1.54 Million CAD | -28.87% |
| 2020 FY | 4.52 Million CAD | 92.96% |
| 2019 Q1 | 814.23 Thousand CAD | 7.57% |
| 2019 FY | 2.34 Million CAD | -25.96% |
| 2019 Q4 | 999.86 Thousand CAD | 1948.77% |
| 2019 Q2 | 482.71 Thousand CAD | -40.72% |
| 2019 Q3 | 48.8 Thousand CAD | -89.89% |
| 2018 Q2 | 599.65 Thousand CAD | 81.37% |
| 2018 Q3 | 1.48 Million CAD | 146.96% |
| 2018 Q1 | 330.61 Thousand CAD | 54.59% |
| 2018 FY | 3.16 Million CAD | 68.45% |
| 2018 Q4 | 756.91 Thousand CAD | -48.89% |
| 2017 Q1 | 230.16 Thousand CAD | -32.14% |
| 2017 Q2 | 148.05 Thousand CAD | -35.67% |
| 2017 Q4 | 213.87 Thousand CAD | -83.56% |
| 2017 FY | 1.88 Million CAD | 91.8% |
| 2017 Q3 | 1.3 Million CAD | 778.39% |
| 2016 FY | 980.57 Thousand CAD | 5.84% |
| 2016 Q2 | 303.11 Thousand CAD | 88.58% |
| 2016 Q3 | 177.54 Thousand CAD | -41.43% |
| 2016 Q4 | 339.17 Thousand CAD | 91.03% |
| 2016 Q1 | 160.73 Thousand CAD | -12.57% |
| 2015 FY | 926.46 Thousand CAD | 148.97% |
| 2015 Q1 | 400.98 Thousand CAD | 172.47% |
| 2015 Q4 | 183.84 Thousand CAD | 19.64% |
| 2015 Q3 | 153.66 Thousand CAD | -18.25% |
| 2015 Q2 | 187.97 Thousand CAD | -53.12% |
| 2014 Q1 | 49.43 Thousand CAD | -9.72% |
| 2014 FY | 372.11 Thousand CAD | 113.4% |
| 2014 Q2 | 53.84 Thousand CAD | 8.93% |
| 2014 Q4 | 147.16 Thousand CAD | 20.95% |
| 2014 Q3 | 121.67 Thousand CAD | 125.98% |
| 2013 Q1 | 29.09 Thousand CAD | -67.67% |
| 2013 FY | 174.37 Thousand CAD | -44.56% |
| 2013 Q4 | 54.75 Thousand CAD | 289.85% |
| 2013 Q2 | 76.49 Thousand CAD | 162.9% |
| 2013 Q3 | 14.04 Thousand CAD | -81.64% |
| 2012 Q4 | 89.98 Thousand CAD | 5.63% |
| 2012 Q3 | 85.18 Thousand CAD | 50.26% |
| 2012 FY | 314.51 Thousand CAD | -26.57% |
| 2012 Q1 | 82.66 Thousand CAD | -3.68% |
| 2012 Q2 | 56.68 Thousand CAD | -31.42% |
| 2011 Q1 | 104.48 Thousand CAD | 34.83% |
| 2011 Q3 | 160.08 Thousand CAD | 105.42% |
| 2011 FY | 428.32 Thousand CAD | 215.09% |
| 2011 Q4 | 85.82 Thousand CAD | -46.39% |
| 2011 Q2 | 77.93 Thousand CAD | -25.41% |
| 2010 Q4 | 77.49 Thousand CAD | 172.77% |
| 2010 Q1 | 98.57 Thousand CAD | 268.27% |
| 2010 Q3 | 28.41 Thousand CAD | 18.19% |
| 2010 FY | 135.93 Thousand CAD | -25.22% |
| 2010 Q2 | 24.03 Thousand CAD | -75.61% |
| 2009 Q1 | 437.79 Thousand CAD | 110.05% |
| 2009 Q2 | 182.54 Thousand CAD | -58.3% |
| 2009 Q3 | 35.66 Thousand CAD | -80.46% |
| 2009 FY | 181.79 Thousand CAD | -83.1% |
| 2009 Q4 | 26.76 Thousand CAD | -24.96% |
| 2008 Q3 | 228.06 Thousand CAD | 13.33% |
| 2008 Q1 | 387.39 Thousand CAD | 180.57% |
| 2008 FY | 1.07 Million CAD | 34.91% |
| 2008 Q4 | 208.42 Thousand CAD | -8.61% |
| 2008 Q2 | 201.24 Thousand CAD | -48.05% |
| 2007 FY | 797.18 Thousand CAD | 38.75% |
| 2007 Q3 | 144.67 Thousand CAD | 13.89% |
| 2007 Q4 | 138.07 Thousand CAD | -4.56% |
| 2007 Q2 | 127.03 Thousand CAD | 5.97% |
| 2007 Q1 | 119.87 Thousand CAD | -9.36% |
| 2006 Q1 | 131.56 Thousand CAD | -50.17% |
| 2006 Q2 | 135.64 Thousand CAD | 3.1% |
| 2006 Q3 | 175.79 Thousand CAD | 29.6% |
| 2006 Q4 | 132.24 Thousand CAD | -24.77% |
| 2006 FY | 574.53 Thousand CAD | -32.49% |
| 2005 FY | 850.97 Thousand CAD | -61.19% |
| 2005 Q4 | 264.01 Thousand CAD | 57.26% |
| 2005 Q3 | 167.88 Thousand CAD | -41.61% |
| 2005 Q2 | 287.5 Thousand CAD | -72.37% |
| 2005 Q1 | 1.04 Million CAD | 131.66% |
| 2004 Q1 | 1.19 Million CAD | 1121.31% |
| 2004 Q4 | 449.23 Thousand CAD | 11.28% |
| 2004 Q3 | 403.71 Thousand CAD | 35.88% |
| 2004 FY | 2.19 Million CAD | 58.91% |
| 2004 Q2 | 297.11 Thousand CAD | -75.06% |
| 2003 Q1 | 45.28 Thousand CAD | 162.9% |
| 2003 FY | 1.37 Million CAD | 516.35% |
| 2003 Q3 | 15.59 Thousand CAD | -79.39% |
| 2003 Q2 | 75.66 Thousand CAD | 67.07% |
| 2003 Q4 | 97.53 Thousand CAD | 525.4% |
| 2002 Q1 | 9073.00 CAD | -89.91% |
| 2002 FY | 223.89 Thousand CAD | 13.53% |
| 2002 Q3 | 92.86 Thousand CAD | 35.55% |
| 2002 Q4 | 17.22 Thousand CAD | -81.45% |
| 2002 Q2 | 68.5 Thousand CAD | 655.09% |
| 2001 FY | 197.2 Thousand CAD | -86.62% |
| 2001 Q3 | 56.7 Thousand CAD | 36.15% |
| 2001 Q2 | 41.64 Thousand CAD | -92.4% |
| 2001 Q1 | 547.68 Thousand CAD | 87.45% |
| 2001 Q4 | 89.95 Thousand CAD | 58.65% |
| 2000 FY | 1.47 Million CAD | 79.84% |
| 2000 Q3 | 378.99 Thousand CAD | 48.54% |
| 2000 Q4 | 292.18 Thousand CAD | -22.91% |
| 2000 Q2 | 255.15 Thousand CAD | -52.61% |
| 2000 Q1 | 538.38 Thousand CAD | 542.63% |
| 1999 Q2 | 69.15 Thousand CAD | -82.94% |
| 1999 Q1 | 405.41 Thousand CAD | 588.95% |
| 1999 FY | 819.61 Thousand CAD | 24.09% |
| 1999 Q3 | 128.29 Thousand CAD | 85.5% |
| 1999 Q4 | 83.77 Thousand CAD | -34.7% |
| 1998 Q2 | 138.84 Thousand CAD | 0.0% |
| 1998 Q4 | 58.84 Thousand CAD | -54.71% |
| 1998 FY | 660.51 Thousand CAD | -46.45% |
| 1998 Q3 | 129.91 Thousand CAD | -6.43% |
| 1997 FY | 1.23 Million CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 96.283% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 34.4% |
| SQZ Biotechnologies Company | 85.61 Million USD | 96.232% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 89.083% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 91.34% |
| Mesoblast Limited | 5.9 Million USD | 45.338% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -114.806% |
| Genus plc | 147.7 Million USD | 97.816% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 63.252% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -140.481% |
| Marizyme, Inc. | 19.23 Million USD | 83.232% |
| ContraFect Corporation | 56.88 Million USD | 94.329% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 61.312% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 26.822% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -118.168% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -10.628% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -15.618% |
| MultiCell Technologies, Inc. | 567.42 USD | -568467.728% |
| Accustem Sciences Inc. | 3.74 Million USD | 13.887% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 96.246% |
| EV Biologics, Inc. | 531.96 Thousand USD | -506.466% |
| Q BioMed Inc. | 3.43 Million USD | 6.124% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 86.947% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -728.144% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -22.784% |
| Biomind Labs Inc. | 994.18 Thousand USD | -224.505% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 98.569% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 51.977% |
| Skye Bioscience, Inc. | 13.54 Million USD | 76.186% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -57.473% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 13004.668% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 36.015% |
| IMV Inc. | 37.7 Million USD | 91.445% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 79.849% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -75.804% |
| GB Sciences, Inc. | 1.42 Million USD | -127.113% |
| Alpha Cognition Inc. | 9.7 Million USD | 66.76% |
| HST Global, Inc. | 140.9 Thousand USD | -2189.572% |
| CSL Limited | 3.44 Billion USD | 99.906% |
| Halberd Corporation | 74.84 Thousand USD | -4210.637% |
| Enzolytics Inc. | 2.17 Million USD | -48.023% |
| Resverlogix Corp. | 12.71 Million USD | 74.621% |
| Affymax, Inc. | 39.38 Million USD | 91.809% |
| SYBLEU INC | 160.87 Thousand USD | -1905.375% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 11.629% |
| argenx SE | 1.53 Billion USD | 99.79% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 94.383% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -209.02% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -104.271% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 5.251% |
| AVAX Technologies, Inc. | 7.31 Million USD | 55.868% |
| Zenith Capital Corp. | 8.94 Million USD | 63.925% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.609% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -18418.839% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -31.395% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1781.048% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 96.752% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -83.338% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -63.596% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -73.043% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 70.312% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -67.95% |
| BioStem Technologies, Inc. | 22.97 Million USD | 85.958% |
| ONE Bio Corp. | 6.44 Million USD | 49.934% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1677.649% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -141.582% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -186.793% |
| Agentix Corp. | 1.37 Million USD | -135.185% |
| LadRx Corporation | 3.81 Million USD | 15.363% |
| Cell Source, Inc. | 4.32 Million USD | 25.413% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -676.493% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -249.338% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -249.338% |
| NovAccess Global Inc. | 2.46 Million USD | -30.786% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -34.148% |
| Itoco Inc. | 919.14 Thousand USD | -250.997% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 23.883% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -188.308% |
| Kadimastem Ltd | 2.41 Million USD | -33.86% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1132.651% |
| CytoDyn Inc. | 18.05 Million USD | 82.134% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -12718.018% |
| Mobile Lads Corp. | 554.54 Thousand USD | -481.767% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1365.92% |
| Qrons Inc. | 643.67 Thousand USD | -401.209% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -127.228% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -44.679% |
| Rebus Holdings, Inc. | 664 Thousand USD | -385.869% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -77.621% |
| International Stem Cell Corporation | 5.27 Million USD | 38.794% |
| Bioxytran, Inc. | 3.82 Million USD | 15.549% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -6028.504% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -15758.856% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 91.104% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -99.392% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -338.436% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -3.702% |
| Neutra Corp. | 243.82 Thousand USD | -1223.17% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 81.519% |
| PureTech Health plc | 144.59 Million USD | 97.769% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 84.255% |
| IXICO plc | 4.7 Million USD | 31.46% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 63.327% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.26% |
| CSL Limited | 3.89 Billion USD | 99.917% |
| Cellectis S.A. | 97.32 Million USD | 96.685% |